Jinyu Bio-Technology CoSHSE:600201 68 EV-to-FCF is 79.30 as of Jul. 11, 2026, which is 70% above its 10-year median of 46.62. GuruFocus rates SHSE:600201 with a GF Score™ of 68/100 and a GF Value™ of ¥8.28 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 330 Biotechnology companies, Jinyu Bio-Technology Co ranks worse than 86.36% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Jinyu Bio-Technology Co's Enterprise Value is ¥12,325 Mil.
Jinyu Bio-Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥155 Mil. Therefore, Jinyu Bio-Technology Co's EV-to-FCF for today is 79.30.
The historical rank and industry rank for Jinyu Bio-Technology Co's EV-to-FCF or its related term are showing as below:
SHSE:600201'
s EV-to-FCF Range Over the Past 10 Years
Min: -1791.47 Med: 46.62 Max: 242.03
Current: 82.09
During the past 13 years, the highest EV-to-FCF of Jinyu Bio-Technology Co was 242.03. The lowest was -1791.47. And the median was 46.62.
SHSE:600201's EV-to-FCF is ranked worse than 86.36% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs SHSE:600201: 82.09
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jinyu Bio-Technology Co (SHSE:600201) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jinyu Bio-Technology Co's PE Ratio (TTM) for today is calculated as:
Jinyu Bio-Technology Co's share price for today is ¥12.18.
Jinyu Bio-Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.086.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600201 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Jinyu Bio-Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinyu Bio-Technology Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jinyu Bio-Technology Co's EV-to-FCF falls into.
Jinyu Bio-Technology Co's current Enterprise Value is ¥12,325 Mil.
Jinyu Bio-Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥155 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinyu Bio-Technology Co (SHSE:600201) has a EV-to-FCF of 79.30 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jinyu Bio-Technology Co and its competitors. This is 70% above median its historical median of 46.62. According to the industry distribution chart, Jinyu Bio-Technology Co ranks #285 out of 330 companies in the Biotechnology industry, placing it in the top 86.4%.
Is Jinyu Bio-Technology Co's EV-to-FCF too high?
Jinyu Bio-Technology Co's current EV-to-FCF of 79.30 is 70% above median its 10-year median of 46.62. The Biotechnology industry median EV-to-FCF is 16.36. Jinyu Bio-Technology Co's value of 79.30 is 384.7% above this industry median. Based on the distribution chart, Jinyu Bio-Technology Co ranks #285 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jinyu Bio-Technology Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jinyu Bio-Technology Co ranks #285 out of 330 companies for EV-to-FCF. This places Jinyu Bio-Technology Co in the lower half of its industry. The industry median EV-to-FCF is 16.36. Jinyu Bio-Technology Co's value of 79.30 is 384.7% above this benchmark. While the company's 10-year median is 46.62 vs. the industry median of 16.36, Jinyu Bio-Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinyu Bio-Technology Co's current EV-to-FCF of 79.30 is 384.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jinyu Bio-Technology Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinyu Bio-Technology Co's current EV-to-FCF is 79.30, which is 70% above median its own 10-year median of 46.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.28, compared to a current price of ¥12.18 — trading 47.1% above its estimated fair value. The current EV-to-FCF is 79.30, which is 70% above median its 10-year median of 46.62 and 384.7% above the Biotechnology industry median of 16.36. Jinyu Bio-Technology Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current EV-to-FCF is 79.30 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued.
The current stock price of ¥12.18 is trading 47.1% above its estimated GF Value™ of ¥8.28.
GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:600201:
EV-to-FCF: 79.30 (70% above median its 10-year median of 46.62)
GF Value™: ¥8.28 vs. price of ¥12.18 (47.1% above fair value)
Industry Position: 384.7% above the Biotechnology median (#285 of 330)
No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
68GF Score
Get the complete analysis for SHSE:600201
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600201 has been successfully added to your 
